Compositions comprising disodium levofolinate
Provided herein are compositions comprising disodium levofolinate. Also provided are processes for preparing compositions comprising disodium levofolinate. Also provided are compositions comprising disodium levofolinate prepared by the processes provided herein. Also provided are methods of treating folic acid deficiency in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering 5-fluorouracil and a composition provided herein to the subject. Also provided are methods of reducing the immediate toxic effects of methotrexate overdose in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering high-dose methotrexate and a composition provided herein to the subject. Also provided are methods of treating megaloblastic anemia in a subject in need thereof, comprising administering a composition provided herein to the subject.
1. A pharmaceutical composition comprising:
a) a lyophilized composition prepared by a process comprising:
1) mixing mannitol and levofolinic acid in sparged water under an inert atmosphere, wherein the ratio of mannitol to levofolinic acid is 3:5 w/w;
2) adding aqueous sodium hydroxide to the levofolinic acid and mannitol mixture;
3) filtering the solution; and
4) lyophilizing the filtered solution such that the lyophilized composition is prepared; wherein the composition comprises 10-formyldihydrofolic acid; and 4-aminobenzoylglutamic acid,
wherein the 10-formyldihydrofolic acid is not more than 0.5% of the mole fraction of the composition, and wherein the temperature of the mixture is maintained at about 15° C. to 17° C. during steps 1) through 3).
2. The composition of claim 1 , wherein the 10-formyldihydrofolic acid is not more than about 0.4% mole fraction of the composition.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is suitable for injection.
4. The pharmaceutical composition of claim 3 , wherein the injectable pharmaceutical composition has a pH of about 7.5 to 8.1.
5. The composition of claim 1 , wherein the composition is dissolved in a diluent.
6. The composition of claim 5 , wherein the diluent is 0.9% saline or 5% dextrose.
7. The composition of claim 5 , wherein the composition comprises about 50 mg/mL of levofolinic acid.
8. The composition of claim 1 , wherein the composition comprises about 175 mg of levofolinic acid.
9. The composition of claim 1 , wherein the composition comprises about 300 mg of levofolinic acid.
10. The pharmaceutical composition of claim 3 , wherein the injectable pharmaceutical composition has a pH of about 7.0 to 8.5.
11. The pharmaceutical composition of claim 3 , wherein the injectable pharmaceutical composition has a pH of about 7.4 to 8.1.
12. The pharmaceutical composition of claim 3 , wherein said injection is intramuscular, intravenous, subcutaneous, or a combination thereof.
13. The pharmaceutical composition of claim 12 , wherein said injection is intramuscular.
14. The pharmaceutical composition of claim 12 , wherein said injection is intravenous.
15. The pharmaceutical composition of claim 12 , wherein said injection is subcutaneous.